Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD
Zydus today announced the initiation of a phase II trial investigating ZYAN1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anemia associated with chronic kidney disease.
July 05, 2017 / 11:44 AM IST
Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD.Source : BSE
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!